Merck said on Wednesday its experimental oral HIV medicine was found to be non-inferior to Gilead Sciences' top-selling drug ...
Merck said on Wednesday that its experimental oral HIV treatment met the main goal of a late-stage trial. The company said ...
Gilead’s investigational drug combo bic/len could help lower the pill burden in patients with virologically suppressed HIV ...
A Brazilian research team has eliminated HIV from a patient’s body for 78 consecutive weeks using only medications, without ...
Opportunistic infections target people with weakened immune systems, including those with HIV. These conditions can lead to ...
Merck & Co. has reported another phase 3 win for islatravir in HIV, advancing its efforts to establish the near-approval ...
Gilead Sciences, Inc. is rated a Buy with robust profitability, solid dividend, prudent M&A and 15-20% upside potential. Read ...
Funding for HIV care and prevention are key for continued progress, but recent cuts to federal funding for health agencies, ...
Merck reports positive results from phase 3 trial of once-daily, oral, two-drug, single-tablet regimen of Doravirine/Islatravir in treatment-naïve adults with HIV-1 infection ...
AllAfrica on MSN
36,000 Liberians Living With HIV/Aids
The National AIDS Commission (NAC) has raised serious concern over a steady increase in HIV cases across Liberia, revealing that the number of people living with the virus has climbed from 34,000 in ...
13don MSN
Early HIV drugs give immune system a brief reprieve before dysregulation returns, study finds
Despite effective HIV medication, the immune system of people with HIV remains disrupted in the long term.
Gilead (GILD) stock gains as the company's new single-tablet HIV regimen is proven as effective as multi-tablet therapies in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback